Biopharmaceutical company focused on neuroscience therapies for central nervous system disorders.
Cerevel Therapeutics Holdings, Inc. is a dynamic clinical-stage biopharmaceutical company focused on advancing innovative therapies for neurological diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, Cerevel Therapeutics is at the forefront of developing treatments that target a range of neuroscience disorders.
The company's pipeline includes promising candidates such as emraclidine, a positive allosteric modulator (PAM) currently undergoing phase 1b clinical trials for schizophrenia. Another key candidate is Darigabat, also a PAM, which is in phase 2 proof-of-concept trials for drug-resistant focal onset seizures in epilepsy, and phase 1 trials for acute anxiety.
Cerevel Therapeutics' diverse portfolio further includes Tavapadon, a selective dopamine D1/D5 partial agonist in phase 3 clinical trials for both early- and late-stage Parkinson's disease. Additionally, CVL-871, a selective dopamine D1/D5 partial agonist, is in phase 2a trials for dementia-related apathy. The company is also advancing CVL-936, a selective dopamine D3-preferring antagonist targeting substance use disorder, currently in phase 1 trials.
Innovation remains central to Cerevel Therapeutics' mission, with ongoing development programs such as CVL-354, a selective kappa-opioid receptor antagonist for major depressive disorder and substance use disorder, and CVL-047, a selective PDE4 inhibitor also targeting these indications. The company is committed to addressing unmet needs in neurological care, with additional programs focused on psychosis and disease progression in Parkinson's through an M4 agonist and LRRK2 inhibitor program respectively. Cerevel Therapeutics continues to push boundaries in neuroscience to improve patient outcomes and quality of life worldwide.